

Prior Authorization Request Form Fax Back To: (866) 940-7328 Phone: (800) 310-6826

Specialty Medication Prior Authorization Cover Sheet

(This cover sheet should be submitted along with a Pharmacy Prior Authorization Medication Fax Request Form. Please refer to www.uhcprovider.com for medication fax request forms.)

Patient Information						
Patient's Name:						
Insurance ID:	Date of Birth:	Height: Weight:				
Address:		Apartment #:				
City:	State:	Zip Code:				
Phone Number:	Alternate Phone:	Sex: ☐ Male ☐ Fem	ale			
Provider Information						
Provider's Name:	Provider ID Number:					
Address:	City:	State: Zip Code:				
Suite Number:	Building Number:					
Phone Number:	Fax number:					
Provider's Specialty:						
Medication Information						
Medication:	Quantity:	ICD10 Code:				
Directions:	Diagnosis:	Refills:				
Physician Signature**:		Initial here if DAW:				
Physician Signature**: By signing above, the physician is providing the specialty pharmacy with a prescription that can be used to facilitate the dispensing and/or coordination of delivery for the requested medication.						
Medication Instructions						
Medication Instructions Has the patient been instructed on how to Self-A	Administer?	☐ Yes ☐ No				
	Administer?	☐ Yes ☐ No				
Has the patient been instructed on how to Self-						
Has the patient been instructed on how to Self- Is this medication a New Start?	Initiation Date: / /	☐ Yes ☐ No				
Has the patient been instructed on how to Self-Alls this medication a New Start? If continuation please provide the following: Is there documentation of positive clinical reserved: **Please attach any pertinent clinical informational clinical information may be needed previously tried and failed.	Initiation Date: / / sponse to current therapy? ation that would pertain to su	☐ Yes ☐ No Date of Last Dose: / / ☐ Yes ☐ No pport stated diagnosis.	n(s)			
Has the patient been instructed on how to Self-Alls this medication a New Start? If continuation please provide the following: Is there documentation of positive clinical research any pertinent clinical informational clinical information may be needed.	Initiation Date: / / sponse to current therapy? ation that would pertain to su	☐ Yes ☐ No Date of Last Dose: / / ☐ Yes ☐ No pport stated diagnosis.	n(s)			
Has the patient been instructed on how to Self-Alls this medication a New Start? If continuation please provide the following: Is there documentation of positive clinical reserved: **Please attach any pertinent clinical informational clinical information may be needed previously tried and failed.	Initiation Date: / / sponse to current therapy? ation that would pertain to sued depending on your patient ian Signature" above and comformation"	☐ Yes ☐ No Date of Last Dose: / / ☐ Yes ☐ No pport stated diagnosis. s plan, including medication plete	n(s)			
Has the patient been instructed on how to Self-Alls this medication a New Start? If continuation please provide the following: Is there documentation of positive clinical reservity the self-Alls and pertinent clinical informational clinical information may be needed previously tried and failed. Delivery Instructions Note: Delivery coordination requires a "Physical "Provider Information" and "Patient Information" and "Patient Information" and "Patient Information"	Initiation Date: / / sponse to current therapy? Ation that would pertain to sued depending on your patient ian Signature" above and comformation" ided free of charge to the patient	☐ Yes ☐ No Date of Last Dose: / / ☐ Yes ☐ No pport stated diagnosis. s plan, including medication plete at at the time of delivery	n(s)			



Lenvima - Washington

PRIOR AUTHORIZATION REQUEST FORM

Please complete this entire form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826.

This form contains multiple pages. Please complete all pages to avoid a delay in our decision.

Allow at least 24 hours for review.

Section A – Member Inforn	lation							
First Name:		Last Name:			Member ID:			
Address:								
City:		State: Z				ZIP Code:		
Phone:		DOB:			Allergies:			
Primary Insurance Information:		•						
Is the requested medication	n 🗆 New or 🗆 C	Continuation	on of Therapy? If c	ontinuation, lis	t star	t date:		
Is this patient currently hos	-	Yes □ No	If recently discha	rged, list disch	arge	date:		
Section B - Provider Inform	nation							
First Name:			Last Name:				M.D./D.O.	
Address:			City:		State		ZIP code:	
Phone:	Fax:		NPI #:		Spec	cialty:		
Office Contact Name / Fax a								
Section C - Medical Inform Medication:	ation				S	trength:		
Directions for use:						uantity:		
Directions for use.					۱	uantity.		
Diagnosis (Please be speci	fic & provide as	much info	rmation as possible)	:	IC	D-10 COD	E:	
Is this member pregnant? Yes No If yes, what is this member's due date?								
Is this member pregnant?	□ Yes □ No	If yes	, what is this mem	ber's due date?	?			
Section D - Previous Medi	cation Trials						_	
	cation Trials	If yes	, what is this mem Directions	ber's due date? Dates of The			on for failure / ontinuation	
Section D - Previous Medi	cation Trials							
Section D - Previous Medi	cation Trials							
Section D - Previous Medi	cation Trials							
Section D - Previous Medi	cation Trials							
Section D – Previous Medinal Medications Section E – Additional infor	cation Trials Stre	ength	Directions of why preferred m	Dates of The	erapy	disc	ontinuation patient's needs:	
Section D – Previous Medinal Medications Section E – Additional infor	cation Trials Stre	ength	Directions	Dates of The	erapy	disc	ontinuation patient's needs:	
Section D – Previous Medinal Medications Section E – Additional infor	cation Trials Stre	ength	Directions of why preferred m	Dates of The	erapy	disc	ontinuation patient's needs:	
Section D – Previous Medinal Medications Section E – Additional infor	cation Trials Stre	ength	Directions of why preferred m	Dates of The	erapy	disc	ontinuation patient's needs:	
Section D – Previous Medinal Medications Section E – Additional infor	cation Trials Stre	ength	Directions of why preferred m	Dates of The	erapy	disc	ontinuation patient's needs:	
Section D – Previous Medinal Medications Section E – Additional infor	cation Trials Stre	ength	Directions of why preferred m	Dates of The	erapy	disc	ontinuation patient's needs:	
Section D – Previous Medinal Medications Section E – Additional infor	cation Trials Stre	ength	Directions of why preferred m	Dates of The	erapy	disc	ontinuation patient's needs:	
Section D – Previous Medinal Medications Section E – Additional infor	cation Trials Stre	ength	Directions of why preferred m	Dates of The	erapy	disc	ontinuation patient's needs:	
Section D – Previous Medinal Medications Section E – Additional infor	cation Trials Stre	ength	Directions of why preferred m	Dates of The	erapy	disc	ontinuation patient's needs:	
Section D – Previous Medi Medications Medications	cation Trials Stre	ength	Directions of why preferred m	Dates of The	erapy	disc	ontinuation patient's needs:	



Physician Signature: _____

Lenvima - Washington

PRIOR AUTHORIZATION REQUEST FORM

Date: __

Member Firs	t name:	Member Last name:	Member DOB:				
Clinical and Drug Specific Information							
ALL REQUESTS							
□ Yes □ No	□ Follicular Carcinoma □ Hürthle Cell Carcinoma	ncer	check which applies)				
□ Yes □ No	Is Lenvima requested for a use supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium? If yes. list supported use:						
		THYROID CANCER					
□ Yes □ No	Does the patient meet one □ Unresectable or locally re □ Metastatic disease □ Persistent locoregional di		eck which applies)				
□ Yes □ No	Does the patient have sym	nptomatic or progressive disease?					
□ Yes □ No	Is the disease refractory to radioactive iodine?						
□ Yes □ No	-	of the following criteria? (If yes, che	eck which applies)				
□ Yes □ No	<u>-</u>	story of failure, contraindication, or and complete Section D above)	intolerance to either of the following?				
RENAL CELL CANCER							
□ Yes □ No			intolerance to prior anti-angiogenic ent (sunitinib), Nexavar (sorafenib)?				
□ Yes □ No	Will Lenvima be used in co	ombination with Afinitor (everolimus	3)?				
HEPATOCELLULAR CARCINOMA							
□ Yes □ No	Does the patient have unre	esectable or metastatic disease?					
CONTINUATION OF THERAPY							
□ Yes □ No	Does the patient show evid	dence of progressive disease while	on Lenvima therapy?				
□ Yes □ No	Does the patient have a do	ocumented positive clinical respons	e to Lenvima therapy?				
	•						

Confidentiality Notice: This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.